Clinical Trials Logo

Vaccine Adverse Reaction clinical trials

View clinical trials related to Vaccine Adverse Reaction.

Filter by:

NCT ID: NCT06286488 Active, not recruiting - Obesity Clinical Trials

Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza

Start date: September 15, 2020
Phase: Phase 4
Study type: Interventional

The aim of the study is to evaluate simultaneously the immunological and clinical efficacy and tolerability of an influenza vaccine, inactivated, quadrivalent, with cleaved virus, in patients at risk for severe and complicated influenza routinely vaccinated against influenza in family medicine clinics or specialty clinics (pediatric, internal medicine, cardiology, gynecological diabetes, pregnant women, transplant).

NCT ID: NCT06180447 Active, not recruiting - Clinical trials for Vaccine Adverse Reaction

Peri-conceptional or Pregnancy Exposure of Vaccination and the Risk of Adverse Pregnancy Outcomes

Start date: January 1, 2024
Phase:
Study type: Observational

Uing data from a population based cohort in China, we will conduct retrospective cohort study to evaluate the risk of vaccine (e.g., HPV/influenza/rabies vaccine) administered during pregnancy (especially during first trimester) for adverse pregnancy outcomes (e.g., birth defects, preterm birth and low birth weight)

NCT ID: NCT05898464 Recruiting - Clinical trials for Vaccine Adverse Reaction

Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV

Start date: June 27, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the immunogenicity and safety of recombinant zoster vaccine according to CD4+ T-cell count and age in people living with HIV, and to provide evidence to guide immunization of people living with HIV.

NCT ID: NCT05735769 Completed - Clinical trials for Vaccine Adverse Reaction

Anti-COVID-19 Vaccine Side Effects

VAX-IT-LEB
Start date: January 1, 2021
Phase:
Study type: Observational

In 2021 and following the COVID-19 (corona virus disease 2019) pandemic, different vaccines were initially authorized in Italy and Lebanon. Notably, vaccine side effects were poorly recorded. Thus, the investigator performed a survey study to monitor COVID-19 vaccine side effects among Italian and Lebanese citizens according to gender and age through a web-based questionnaire in Italian and Arabic languages including 21 items by "Google Form", investigating 13 symptoms, and employing social-media platforms

NCT ID: NCT05546502 Recruiting - Vaccine Reaction Clinical Trials

Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children

Start date: October 9, 2022
Phase: Phase 3
Study type: Interventional

A Phase III, Observer-blind, randomized, active-controlled prospective intervention study

NCT ID: NCT05489367 Completed - Fertility Disorders Clinical Trials

Does COVÄ°D-19 m-RNA Vaccine Affect Fertility and Over Reserve ?

Start date: February 1, 2022
Phase:
Study type: Observational [Patient Registry]

Women's ovarian reserve and fertility were compared before and after 2 doses of vaccination

NCT ID: NCT05483725 Active, not recruiting - COVID-19 Clinical Trials

Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.

Start date: October 4, 2021
Phase:
Study type: Observational

Prospective observational trial to assess immunological safety (anti-HLA antibodies, donor-derived cell-free DNA) and immunological effectiveness (anti-SARS-CoV-2 IgG) of the first booster dose of SARS-CoV-2 mRNA vaccines in kidney transplant recipients at least one year from transplantation.

NCT ID: NCT05482295 Not yet recruiting - Vaccine Reaction Clinical Trials

Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)

Start date: June 2024
Phase: Phase 3
Study type: Interventional

This is a phase 3 study, experimental, randomized, double blind, four arm parallel group study, lot to lot consistency. The primary objective of this study is to assess the protectivity of In-House Recombinant Hepatitis B vaccine 28 days after 3 doses immunization.

NCT ID: NCT05409300 Active, not recruiting - COVID-19 Clinical Trials

Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea

CovicompareG
Start date: April 25, 2022
Phase: Phase 2
Study type: Interventional

Phase II, non-randomized, open-label, comparative, single center national trial in Guinea, aimed to assess the humoral vaccine immune response induced by BBIBP-CorV vaccine in 200 adults aged between 18 and 45 years or 55 or older, one month after receiving the complete COVID-19 vaccination schedule.

NCT ID: NCT05409261 Active, not recruiting - COVID-19 Clinical Trials

Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine

CoviComMali
Start date: June 2, 2022
Phase: Phase 2
Study type: Interventional

Phase II, non-randomized, open-label, comparative, national, multicenter trial in Mali, aimed to assess the humoral vaccine immune response induced by Ad26.COV2.S vaccine in 200 adults one month after receiving the complete vaccination schedule of SARS-CoV-2 vaccine.